**DTaP-HepB-IPV Combination Vaccine (PEDIARIX®)**

**Precautions and Contraindications**

Screen all patients for precautions and contraindications to immunization.

**Recommended Schedule**

DTaP-HepB-IPV is approved for the primary series routinely given at 2, 4 and 6 months of age. The recommended interval between doses is 6 to 8 weeks (preferably 8 weeks).

DTaP-HepB-IPV is approved for use in children aged 6 weeks through 6 years (prior to the 7th birthday). A child who is behind schedule can still receive DTaP-HepB-IPV as long as it is given for doses 1, 2 or 3 of the series and the child is less than 7 years of age.

DTaP-HepB-IPV can be used to complete the primary series in infants who have begun with the separate vaccines.

Children who have received DTaP-HepB-IPVcan also receive TriHIBit**®**(DTaP‑Hib) to complete the 4th dose of the DTaP and *Haemophilus influenzae* typeb (Hib) series -- as long as it is the final dose in the Hib series, and the child has received at least one prior dose of Hib vaccine.

DTaP-HepB-IPVcan be administered simultaneously with other vaccines given at separate injection sites, including Hib and pneumococcal conjugate (PCV7 is listed in the latest package insert) vaccines. Please refer to the section below on **Adverse Events** for additional information.

**Minimum Ages and Intervals**

* The recommended minimum age and interval for each dose are equivalent to the oldest age or longest interval recommended for any of the individual components for that dose. For example, the minimum age for dose #1 is 6 weeks (the same as DTaP and IPV), while the minimum age for the third dose is 24 weeks (the same as HepB).
* If an accelerated schedule is used, the minimum interval between the 1st and 2nd doses is 6 weeks; and between the 2nd and 3rd doses is 8 weeks, but the 3rd dose should **not** be given before age 24 weeks. Please refer to the table below.

|  |  |  |
| --- | --- | --- |
| **Dose** | **Minimum Age** | **Minimum Interval from Previous Dose** |
| 1 | 6 weeks | - |
| 2 | 10 weeks | 6 weeks |
| 3 | 24 weeks | 8 weeks\* |
| \*And not before 24 weeks of age | | |

Children who have fallen out of the regular schedule may also receive **PEDIARIX®** for the primary series up to the age of 7 years.

**Dosage and Route**

Give **PEDIARIX®** vaccine 0.5 mL intramuscularly (IM).

**Always check the package insert prior to administration of any vaccine**.

**Anatomical Site**

The preferred sites are the anterolateral aspects of the thigh or into the deltoid muscle. The vaccine should not be injected into the gluteal area or areas where there is a major nerve trunk.

**Precautions**

* Moderate to severe illness, with or without fever (temporary precaution)
* **PEDIARIX®** should be given with caution in children with bleeding disorders such as hemophilia or thrombocytopenia, with steps taken to avoid the risk of hematoma following injection.
* As with other intramuscular injections, use with caution in patients on anticoagulant therapy.
* As with any vaccine, if administered to immunosuppressed persons, including individuals receiving immunosuppressive therapy, the expected immune response may not be obtained. See package insert about immunosuppressive therapies.
* While the single dose vial is latex-free, the tip cap and rubber plunger of the needle-less, pre-filled syringes contains dry natural rubber latex that may cause allergic reactions in latex sensitive individuals.

**Contraindications**

Individuals with:

* Anaphylactic reaction to previous dose of this vaccine or with any component of this vaccine (see package insert).
* Hypersensitivity to any component of the vaccine, including yeast, neomycin, and polymyxin B, is a contraindication.
* This vaccine is not recommended for persons before the age of 6 week or for those persons 7 years of age and older.
* The contraindications and precautions for DTaP-HepB-IPVare the same as they would be for any of its individual component vaccines. Please refer to the package insert for a complete list of contraindications and precautions and to immunization protocols for individual component vaccines.
* Encephalopathy within 7 days of administration of a previous dose of a pertussis containing vaccine
* Evolving neurologic disease, including infantile spasms, epilepsy or progressive encephalopathy

**Adverse Events**

* See the product’s package insert
* See Adverse Events Following Vaccinations page of this section

**Storage and Handling**

* Store in refrigerator at 36oF – 46oF (2oC – 8oC)
* DO NOT FREEZE; discard if product has been frozen.

**Additional Information**

* Vaccine Information Statements

There is not a specific Vaccine Information Statement (VIS) for **PEDIARIX®**. When administering a combination vaccine, the VISs for the individual component vaccines must be supplied. DTaP-HepB-IPV may be used interchangeably with other pertussis-containing or HepB vaccines.

* DTaP-HepB-IPV is considered preservative-free. However, a trace amount of thimerosal (<0.0125 mcg/0.5 mL) is present.

**References:**

Package Insert – PEDIARIX (Dated 10/2016), [https://www.gsksource.com/pharma/content/dam/GlaxoSmithKline/US/en/Prescribing\_Information/Pediarix/pdf/PEDIARIX.PDF](https://www.cdc.gov/vaccines/schedules/downloads/child/0-18yrs-child-combined-schedule.pdf).

Last updated August 1, 2012 and July 1, 2017